Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis
15
lượt xem 0
download
lượt xem 0
download
Download
Vui lòng tải xuống để xem tài liệu đầy đủ
Zalypsis® is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing’s sarcoma. However, the determinants of the response to Zalypsis are not well known. The identification of biomarkers for Zalypsis activity would also contribute to broaden the spectrum of tumors by selecting those patients more likely to respond to this therapy.
Chủ đề:
Bình luận(0) Đăng nhập để gửi bình luận!
CÓ THỂ BẠN MUỐN DOWNLOAD